Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Japan Co. Ltd.
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who completed the evaluation period (Week 16) of N165 Clinical Trial of L059
Patients/the parent or guardian wish to continue treatment with L059 and to enter N165 Follow-up Study, and also the investigator admit the necessity of the repeated intake of the investigational drug for the patients.
You may not be if
Patients who had not participate in N165 Clinical Trial of L059.
Patients who had participated in N165 Clinical Trial of L059 with no intention of entering the follow-up study taking the same medication.
Patients had not been in compliance with requirements of Protocol for N165 Clinical Trial of L059 in the course of the study.
